Literature DB >> 16477808

Mitochondrial cholesterol transport: a possible target in the management of hyperlipidemia.

E A Hall1, S Ren, P B Hylemon, K Redford, A del Castillo, G Gil, W M Pandak.   

Abstract

Sterol 27-hydroxylase (CYP27A1) may defend cells against accumulation of excess cholesterol, making this enzyme a possible target in the management of hyperlipidemia. The study objective was to analyze cholesterol homeostatic responses to increases in CYP27A1 activity in HepG2 cells and primary human hepatocytes. Increasing CYP27A1 activity by increasing enzyme expression led to significant increases in bile acid synthesis with compensatory increases in HMG-CoA reductase (HMGR) activity/protein, LDL receptor (LDLR) mRNA, and LDLR-mediated cholesterol uptake. Under these conditions, only a small increase in cellular 27-hydroxycholesterol (27OH-Chol) concentration was observed. No changes were detected in mature sterol regulatory element-binding proteins (SREBP) 1 or 2. Increasing CYP27A1 activity by increasing mitochondrial cholesterol transport (i.e., substrate availability) led to greater increases in bile acid synthesis with significant increases in cellular 27OH-Chol concentration. Mature SREBP 2 protein decreased significantly with compensatory decreases in HMGR protein. No change was detected in mature SREBP 1 protein. Despite increasing 27OH-Chol and lowering SREBP 2 protein concentrations, LDLR mRNA increased significantly, suggesting alternative mechanisms of LDLR transcriptional regulation. These findings suggest that regulation of liver mitochondrial cholesterol transport represents a potential therapeutic strategy in the treatment of hyperlipidemia and atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16477808     DOI: 10.1007/s11745-005-1491-0

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  43 in total

1.  Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes.

Authors:  Liang Qiao; Adly Yacoub; Elaine Studer; Seema Gupta; Xin Yan Pei; Steven Grant; Philip B Hylemon; Paul Dent
Journal:  Hepatology       Date:  2002-04       Impact factor: 17.425

2.  Overexpression of CYP27 in hepatic and extrahepatic cells: role in the regulation of cholesterol homeostasis.

Authors:  E Hall; P Hylemon; Z Vlahcevic; D Mallonee; K Valerie; N Avadhani; W Pandak
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2001-07       Impact factor: 4.052

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Side chain hydroxylations in bile acid biosynthesis catalyzed by CYP3A are markedly up-regulated in Cyp27-/- mice but not in cerebrotendinous xanthomatosis.

Authors:  A Honda; G Salen; Y Matsuzaki; A K Batta; G Xu; E Leitersdorf; G S Tint; S K Erickson; N Tanaka; S Shefer
Journal:  J Biol Chem       Date:  2001-07-13       Impact factor: 5.157

5.  Structural specificity in the suppression of HMG-CoA reductase in human fibroblasts by intermediates in bile acid biosynthesis.

Authors:  M Axelson; O Larsson; J Zhang; J Shoda; J Sjövall
Journal:  J Lipid Res       Date:  1995-02       Impact factor: 5.922

6.  Ketoconazole and 25-hydroxycholesterol produce reciprocal changes in the rate of transcription of the human LDL receptor gene.

Authors:  J L Ellsworth; A J Carlstrom; J Deikman
Journal:  Biochim Biophys Acta       Date:  1994-01-20

7.  Differences between the regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and low density lipoprotein receptor in human hepatoma cells and fibroblasts reside primarily at the translational and post-translational levels.

Authors:  S P Tam; L Brissette; R Ramharack; R G Deeley
Journal:  J Biol Chem       Date:  1991-09-05       Impact factor: 5.157

8.  SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis.

Authors:  X Wang; R Sato; M S Brown; X Hua; J L Goldstein
Journal:  Cell       Date:  1994-04-08       Impact factor: 41.582

9.  Regulation of sterol 27-hydroxylase and an alternative pathway of bile acid biosynthesis in primary cultures of rat hepatocytes.

Authors:  R T Stravitz; Z R Vlahcevic; T L Russell; M L Heizer; N G Avadhani; P B Hylemon
Journal:  J Steroid Biochem Mol Biol       Date:  1996-03       Impact factor: 4.292

10.  Atherosclerosis and sterol 27-hydroxylase: evidence for a role of this enzyme in elimination of cholesterol from human macrophages.

Authors:  I Björkhem; O Andersson; U Diczfalusy; B Sevastik; R J Xiu; C Duan; E Lund
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-30       Impact factor: 11.205

View more
  4 in total

Review 1.  Hormonal and Genetic Regulatory Events in Breast Cancer and Its Therapeutics: Importance of the Steroidogenic Acute Regulatory Protein.

Authors:  Pulak R Manna; Ahsen U Ahmed; Deborah Molehin; Madhusudhanan Narasimhan; Kevin Pruitt; P Hemachandra Reddy
Journal:  Biomedicines       Date:  2022-06-03

2.  Plasma from systemic lupus patients compromises cholesterol homeostasis: a potential mechanism linking autoimmunity to atherosclerotic cardiovascular disease.

Authors:  Allison B Reiss; Kamran Anwar; Joan T Merrill; Edwin S L Chan; Nahel W Awadallah; Bruce N Cronstein; H Michael Belmont; Elise Belilos; Gary Rosenblum; Kristina Belostocki; Lois Bonetti; Kowser Hasneen; Steven E Carsons
Journal:  Rheumatol Int       Date:  2009-06-23       Impact factor: 2.631

3.  ABCC6- a new player in cellular cholesterol and lipoprotein metabolism?

Authors:  Patricia Kuzaj; Joachim Kuhn; Mareike Dabisch-Ruthe; Isabel Faust; Christian Götting; Cornelius Knabbe; Doris Hendig
Journal:  Lipids Health Dis       Date:  2014-07-27       Impact factor: 3.876

4.  Protective effects of mitochondrial fission inhibition on ox-LDL induced VSMC foaming via metabolic reprogramming.

Authors:  Yijin Fang; Yu Zhu; Yue Wu; Liangming Liu; Huadong Wang
Journal:  Front Pharmacol       Date:  2022-09-02       Impact factor: 5.988

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.